Table 1. Patient characteristics and number of samples used in different assays.
NA, not applicable.
| Characteristics | Hong Kong cohort | Atlanta cohort |
| Number of subjects | ||
| COVID-19 | 36 patients* | 40 patients* |
| Flu/RSV | NA | 16 patients |
| Healthy | 45 individuals | 24 individuals |
| Age | ||
| COVID-19 [median (range)] | 55 (18–80) | 56 (25–94) |
| Flu/RSV | NA | 66 (51–86) |
| Healthy | 53 (21–69) | 52 (23–91) |
| Gender | ||
| COVID-19 (male, %) | 58% | 55% |
| Flu/RSV (male, %) | NA | 31% |
| Healthy (male, %) | 58% | 42% |
| Clinical severity of COVID-19 patients | ||
| Mild/moderate | 75% | 18% |
| Severe (no ICU) | 14% | 60% |
| ICU | 11% | 18% |
| Clinical severity of flu/RSV patients | ||
| Mild/moderate | NA | 37.5% |
| Severe (no ICU) | NA | 37.5% |
| ICU | NA | 31% |
| Intervention | ||
| IFN-β1 | 20% | NA |
| Corticosteroids | 19% | NA |
| Antivirals | 61% | NA |
| Assays using COVID-19 samples | ||
| Phospho-CyTOF | 54 PBMC samples (36 patients) | 19 PBMC samples (16 patients) |
| In vitro stimulation | NA | 17 PBMC samples (15 patients) |
| Olink proteomics | NA | 36 plasma samples (29 patients) |
| CITE-seq | NA | 7 PBMC samples (7 patients) |
| Bulk RNA-seq | NA | 17 PBMC samples (15 patients) |
| Bacterial products | NA | 51 plasma samples (40 patients) |
| Assays using flu/RSV samples | ||
| Phospho-CyTOF | NA | 4 PBMC samples (4 patients) |
| Olink proteomics | NA | 19 plasma samples (16 patients) |
*Some patients have blood from multiple time points.